# ğŸ“Š Clinical Trial Power Analysis: Multi-Endpoint Dose Comparison

This R project performs a **Monte Carlo simulation study** to evaluate statistical power in clinical trials with multiple endpoints and dose comparisons, focusing on Type 2 diabetes treatment trials.

## ğŸ¯ Project Overview

The simulation evaluates three doses (0.25 mg, 0.50 mg, 0.80 mg) against placebo using **two primary endpoints**:
1. **Hemoglobin A1c (HbA1c)** â€“ Primary glycemic control marker
2. **Fasting Serum Glucose** â€“ Secondary glycemic endpoint

The study investigates:
- **Statistical power** across different multiple testing procedures
- **Impact of sample size** on power
- **Effect of endpoint correlation** on inference
- **Dose-response relationships**
- **Weight allocation in fallback procedures**

## ğŸ§ª Methodology

### ğŸ“ˆ Statistical Framework
- **Multiple Testing Procedures**:
  - Fixed-sequence testing
  - Fallback procedure with weighted alpha allocation
  - Gatekeeping procedures (for three endpoints)
- **Simulation Design**:
  - Monte Carlo simulations (n=1000â€“100,000 iterations)
  - Multivariate normal data generation (`mvtnorm` package)
  - Two-sample t-tests for endpoint comparisons
- **Parameters Varied**:
  - Sample size (40â€“150 per arm)
  - Endpoint correlation (Ï = 0â€“1)
  - Standardized effect sizes (0.25â€“1.0)
  - Alpha allocation weights

### ğŸ”¬ Key Analyses
1. **Dose Comparison**: Identify the most statistically significant dose
2. **Power Analysis**: Empirical power calculation for each endpoint
3. **Parameter Sensitivity**: Impact of correlation, sample size, and effect size
4. **Visualization**: ggplot2 plots showing relationships between parameters and power

## ğŸ“Š Key Findings
# ğŸ” Dose Selection
Dose B (0.50 mg) showed the most statistically significant results across endpoints

Clear dose-response relationship observed

Clinical relevance considered (effects > 0.4 deemed meaningful)

## âš¡ Power Characteristics
Sample size has strong positive correlation with power (Ï â‰ˆ 0.8â€“0.9)

Endpoint correlation shows complex, sometimes counterintuitive effects on power

Standardized effect size strongly influences power, particularly for the corresponding endpoint

## âš–ï¸ Multiple Testing Insights
Fixed-sequence procedure: Conservative but clear hierarchical testing

Fallback procedure: More flexible with weighted alpha allocation

Weight distribution significantly impacts endpoint-specific power

Optimal when prioritizing clinically important endpoints

## ğŸ“ˆ Visualizations
The project generates several insightful plots:

Power vs. Sample Size: Positive logarithmic relationship

Power vs. Correlation: Complex, sometimes paradoxical patterns

Power vs. Effect Size: Expected positive monotonic relationships

Dose Comparison: Visual ranking of treatment efficacy

## ğŸ› ï¸ Technical Implementation
# ğŸ”§ Core Functions
Data Generation: rmvnorm() for correlated endpoints

Statistical Testing: t.test() with multiple comparison adjustments

Power Calculation: Empirical proportion of significant results

Visualization: ggplot2 with custom themes and annotations

## ğŸ“¦ Key Packages
mvtnorm: Multivariate normal simulation

ggplot2: Publication-quality graphics

gMCP: Graphical multiple comparison procedures (optional)

## ğŸ“ Interpretation Notes
# ğŸ² Simulation Assumptions
Endpoints initially assumed independent (Ï = 0)

Equal variance across treatment arms

Normally distributed endpoint measurements

Balanced randomization (equal sample sizes)

## âš ï¸ Limitations & Considerations
Simplified covariance structures

Assumption of known variance parameters

Focus on type I error control rather than clinical significance

Results specific to chosen parameter ranges

## ğŸ”® Future Extensions
Potential enhancements:

Bayesian approaches for dose finding

Adaptive designs with sample size re-estimation

Time-to-event endpoints (survival analysis)

Patient subgroup analyses

Cost-effectiveness integration

## ğŸ“š References
Bretz, F., Maurer, W., Brannath, W., & Posch, M. (2009). A graphical approach to sequentially rejective multiple test procedures. Statistics in Medicine.

Dmitrienko, A., & Tamhane, A. C. (2007). Multiple testing problems in pharmaceutical statistics. Chapman and Hall/CRC.

European Medicines Agency. (2017). Guideline on multiplicity issues in clinical trials.

# ğŸ‘¨â€ğŸ”¬ Author
Rezaul Karim Tusar,
MSc Epidemiology,
LMU MÃ¼nchen
